Deciphera price target raised to $22 from $20 at Stifel

Stifel raised the firm’s price target on Deciphera to $22 from $20 and keeps a Buy rating on the shares. Vimseltinib’s pivotal data “look approvable” in the U.S. and support a view that the drug can achieve higher sales potential than Turalio on a differentiated label, says the analyst. Following the data, the firm has increased confidence in a vimseltinib U.S. approval with a differentiated label that will allow a second-to-market drug to “win and expand the TGCT market,” the analyst added.